tenofovir alafenamide fumarate ( taf ) is the pro - drug of tenofovir with advantages of slight increase activity and reduced renal / bone toxicity . the phase 2 trial ( zolopa a. 2012 croi , abstr 99 lb ) compared taf vs. another tdf prodrug ( tfv , each with efv , cobi / ftc in 170 treatment nave patients . at 24 weeks both groups achieved vl < 50 c / ml ; taf showed better renal and bone safety . dolutgravir ( dtg)new once daily dtg/2nrtis that shows potency with good activity vs. ral - resistant strains .  s / gsk 1265 - 744 ( 744  ) : this is a next generation insti with a t1/2 of 21 - 50d ! mk1439this new potent nnrti showed exceptional potency with 25 mg monotherapy once daily ( anderson m , 2013 croi ; abstr . rpv - la : a novel nanosuspension of rpv with steady state release after 600 mg given sc or i m every 3 months . cenicriviroc ( cvc ) antagonizes ccr5 receptor , but also ccr-2 receptors to possibly reduce immune activation . bms 663068 ( or bms 068 ) : this is a prodrug of bms-529 that binds gp125 to prevent hiv binding to cd4 cells . a small trial showed 42 of 48 treatment - nave patients responded ; the 6 exceptions had a genetic factor that accounted for nonresponse . cobicistat ( cobi ) is a potential substitute for rtv to boost arvs and is already fda - approved in combination as evg / cobi / tdf / ftc .
new drugs by classnrti : tenofovir alafenamide fumarate ( taf ) is the pro - drug of tenofovir with advantages of slight increase activity and reduced renal / bone toxicity . the phase 2 trial ( zolopa a. 2012 croi , abstr 99 lb ) compared taf vs. another tdf prodrug ( tfv , each with efv , cobi / ftc in 170 treatment nave patients . at 24 weeks 
 both groups achieved vl < 50 c / ml ; taf showed better renal and bone safety.insti:dolutgravir ( dtg)new once daily dtg/2nrtis that shows potency with good activity vs. ral - resistant strains. s / gsk 1265 - 744 ( 744  ) : this is a next generation insti with a t1/2 of 21 - 50d!nnrti : mk1439this new potent nnrti showed exceptional potency with 25 mg monotherapy once daily ( anderson m , 2013 croi ; abstr . 
 100). rpv - la : a novel nanosuspension of rpv with steady state release after 600 mg given sc or i m every 3 months.entry inhibitors : cenicriviroc ( cvc ) antagonizes ccr5 receptor , but also ccr-2 receptors to possibly reduce immune activation . 
 art activity is comparable to efv. bms 663068 ( or bms 068 ) : this is a prodrug of bms-529 that binds gp125 to prevent hiv binding to cd4 cells . 
 a small trial showed 42 of 48 treatment - nave patients responded ; the 6 exceptions had a genetic factor that accounted for nonresponse.pharmacoenhancer:cobicistat ( cobi ) is a potential substitute for rtv to boost arvs and is already fda - approved in combination as evg / cobi / tdf / ftc .